Granulomatous liver diseases
Maria Mironova(National Institutes of Health), Theo Heller(National Institutes of Health), Christopher Koh(National Institutes of Health), Harish Gopalakrishna(National Institute of Diabetes and Digestive and Kidney Diseases), Gian Rodriguez Franco(National Institutes of Health), Steven M. Holland(National Institute of Allergy and Infectious Diseases), David E. Kleiner(National Institutes of Health)
Cited by 25
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Activated STING in a Vascular and Pulmonary Syndrome
|New England Journal of Medicine|2014|1.4k
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
|New England Journal of Medicine|2021|1.1k